371 related articles for article (PubMed ID: 23569307)
1. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.
Ji Y; Wang SJ
J Clin Oncol; 2013 May; 31(14):1785-91. PubMed ID: 23569307
[TBL] [Abstract][Full Text] [Related]
2. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
Horton BJ; Wages NA; Conaway MR
Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
[TBL] [Abstract][Full Text] [Related]
3. The 3 + 3 design in dose-finding studies with small sample sizes: Pitfalls and possible remedies.
Chiuzan C; Dehbi HM
Clin Trials; 2024 Jun; 21(3):350-357. PubMed ID: 38618916
[TBL] [Abstract][Full Text] [Related]
4. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
5. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.
Yuan Y; Hess KR; Hilsenbeck SG; Gilbert MR
Clin Cancer Res; 2016 Sep; 22(17):4291-301. PubMed ID: 27407096
[TBL] [Abstract][Full Text] [Related]
6. Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials.
Yan F; Mandrekar SJ; Yuan Y
Clin Cancer Res; 2017 Aug; 23(15):3994-4003. PubMed ID: 28546227
[TBL] [Abstract][Full Text] [Related]
7. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
8. Choice of designs and doses for early phase trials.
Zhou Y
Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
[TBL] [Abstract][Full Text] [Related]
9. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
Tighiouart M; Li Q; Rogatko A
Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
[TBL] [Abstract][Full Text] [Related]
10. A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.
Guo W; Wang SJ; Yang S; Lynn H; Ji Y
Contemp Clin Trials; 2017 Jul; 58():23-33. PubMed ID: 28458054
[TBL] [Abstract][Full Text] [Related]
11. R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials.
Guo W; Ji Y; Li D
J Biopharm Stat; 2019; 29(3):411-424. PubMed ID: 30744484
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS).
Pan H; Xie F; Liu P; Xia J; Ji Y
Clin Trials; 2014 Feb; 11(1):49-59. PubMed ID: 24137041
[TBL] [Abstract][Full Text] [Related]
13. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
James GD; Symeonides S; Marshall J; Young J; Clack G
BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
[TBL] [Abstract][Full Text] [Related]
14. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
15. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
16. A modified toxicity probability interval method for dose-finding trials.
Ji Y; Liu P; Li Y; Bekele BN
Clin Trials; 2010 Dec; 7(6):653-63. PubMed ID: 20935021
[TBL] [Abstract][Full Text] [Related]
17. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
18. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.
Zhou H; Yuan Y; Nie L
Clin Cancer Res; 2018 Sep; 24(18):4357-4364. PubMed ID: 29661774
[TBL] [Abstract][Full Text] [Related]
19. Dose-finding design for multi-drug combinations.
Wages NA; Conaway MR; O'Quigley J
Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
[TBL] [Abstract][Full Text] [Related]
20. Escalation strategies for combination therapy Phase I trials.
Sweeting MJ; Mander AP
Pharm Stat; 2012; 11(3):258-66. PubMed ID: 22411472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]